medrol
pfizer new zealand limited - methylprednisolone 4mg; methylprednisolone 4mg - tablet - 4 mg - active: methylprednisolone 4mg excipient: calcium stearate lactose monohydrate liquid paraffin purified water sucrose active: methylprednisolone 4mg excipient: calcium stearate lactose monohydrate maize starch purified water sucrose - primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). · congenital adrenal hyperplasia. · nonsuppurative thyroiditis · hypercalcemia associated with cancer
medrol pak 4 mg tabl.
pfizer sa-nv - methylprednisolone 4 mg - tablet - 4 mg - methylprednisolone 4 mg - methylprednisolone
medrol 4 mg tablet
pfizer canada ulc - methylprednisolone - tablet - 4mg - methylprednisolone 4mg - adrenals
medrol tablets 4mg (メドロール錠4mg)
pfizer pharmaceuticals inc. - methylprednisolone - white tablet with split line, major axis: 8.2 mm, minor axis: 5.6 mm, thickness: 2.2 mm
medrol tablet 4mg
pfizer australia pty ltd - methylprednisolone -
medrol 4 mg tabl.
pfizer sa-nv - methylprednisolone 4 mg - tablet - 4 mg - methylprednisolone 4 mg - methylprednisolone
medrol tab 4 mg tablet
pfizer - methylprednisolone - tablet - 4 mg
medrol 4mg 4mg/tablet
modern pharmaceutical company italy - 30's hdpe bottle - tablet - 4mg/tablet - endocrine system-corticosteroids
medrol tablet
pfizer laboratories limited 197 lenana road - nairobi - methylprednisolone - tablet - 4mg - plain weak corticosteroids (group i) for topical
medrol- methylprednisole tablet
stat rx usa - methylprednisolone (unii: x4w7zr7023) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone 4 mg - medrol tablets are indicated in the following conditions: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis synovitis of osteoarthritis acute nonspecific tenosynovitis post-traumatic osteoarthritis psoriatic arthritis epicondylitis acute gouty arthritis during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus systemic dermatomyositis (polymyositis) acute rheumatic carditis bullo